Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas
Latest Information Update: 07 Nov 2021
At a glance
- Drugs ENMD 2076 (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 14 Aug 2018 Primary endpoint (Number of patients with and without disease progression at 6 months after treatment) has not been met, according to results published in the Clinical Cancer Research.
- 14 Aug 2018 Results published in the Clinical Cancer Research.
- 15 Feb 2018 Status changed from active, no longer recruiting to completed.